What are the recommended management strategies for an adult male with partial androgen insensitivity syndrome?

Management of Adult Males with Partial Androgen Insensitivity Syndrome

Adult males with partial androgen insensitivity syndrome (PAIS) should NOT receive standard testosterone replacement therapy, as they have androgen receptor mutations causing tissue resistance to androgens; instead, management focuses on surgical correction of gynecomastia, psychological support, and fertility preservation strategies using gonadotropins if fertility is desired.

Key Clinical Considerations

The fundamental issue in PAIS is that the androgen receptor itself is defective 1, 2, 3. This means that simply providing more testosterone—the standard approach for typical androgen deficiency—will not effectively address the underlying problem since the cellular machinery to respond to androgens is impaired.

Why Standard Testosterone Therapy Fails in PAIS

Adult males with PAIS typically already have markedly elevated endogenous testosterone and LH levels 2, 3. Adding exogenous testosterone would:

• Further suppress spermatogenesis through negative feedback 4
• Provide no additional virilization benefit due to receptor resistance
• Potentially worsen gynecomastia through aromatization to estrogen

The laboratory pattern in PAIS is distinctive: elevated testosterone, estradiol, SHBG, and LH, but normal FSH and inhibin B 2. This contrasts sharply with classical androgen deficiency where testosterone is unequivocally low 5, 6.

Specific Management Algorithm

1. Gynecomastia Management (Most Common Issue)

Gynecomastia occurs in 91% of genetically confirmed PAIS cases, typically developing around age 13.5 years 1.

Surgical approach is superior to medical therapy:

• Median clinician effectiveness score: 10/10 for surgery vs 3/10 for medical therapy (P < 0.0001) 1
• Only 6% show spontaneous resolution 1
• Surgery typically performed around age 15.7 years 1
• Recommendation: Proceed directly to surgical mastectomy rather than prolonged medical trials 1

2. Micropenis Management

Micropenis is present in 77% of PAIS patients at the time of gynecomastia development 1.

Topical dihydrotestosterone (DHT) gel 2.5%:

• Dose: 0.3 mg/kg body weight daily applied to penis
• Duration: 4-month course
• Efficacy varies by age:
  • Pre-pubertal: +40% increase in stretched penile length 7
  • Peri-pubertal: +63% increase 7
  • Post-pubertal adults with prior testosterone exposure: No additional benefit 7
• Critical timing: Most effective before or during puberty, not after 7

Standard intramuscular testosterone therapy shows variable and often disappointing results for penile growth in PAIS, even with high doses 2, 7.

3. Fertility Considerations

For males with PAIS desiring fertility:

DO NOT use exogenous testosterone 4:

• Suppresses spermatogenesis through hypothalamic-pituitary negative feedback
• Recovery may take months to years after cessation
• Contraindicated in anyone pursuing near-term fertility

Instead, use gonadotropin therapy:

• First-line: Human chorionic gonadotropin (hCG) 500-2500 IU, 2-3 times weekly 4
• Add FSH injections after testosterone normalization if needed 4
• Consider 2-4 months of FSH alone before hCG for improved outcomes 8
• If medical therapy fails but sperm present in ejaculate: refer for IUI or ART 4

4. Psychological Support

42% of PAIS patients receive psychology support 1, but this likely underestimates need given:

• Gender dysphoria occurs in up to 25% of 46,XY DSD patients raised male 9
• Complex psychosocial issues around sexual function, body image, and fertility
• Recommendation: Proactive referral to experienced DSD psychology specialists, not reactive 9, 10, 11

5. Gonadal Management

Unlike complete AIS where gonadectomy is standard due to malignancy risk, management in PAIS depends on phenotype and gonadal position:

• Scrotal testes require surveillance for tumor development 9
• Timing of gonadectomy remains controversial and should be individualized based on malignancy risk vs hormone production needs 3, 10, 11

Critical Pitfalls to Avoid

1. Do not apply standard androgen deficiency guidelines 5, 6 to PAIS—these are for men with normal androgen receptors and low testosterone, not receptor mutations with high testosterone

2. Do not prescribe testosterone for fertility preservation—this will worsen fertility outcomes 4

3. Do not delay gynecomastia surgery waiting for medical therapy to work—surgery is definitively more effective 1

4. Do not attempt penile growth interventions after puberty with prior testosterone exposure—window of opportunity has closed 7

5. Do not diagnose based on phenotype alone—genetic confirmation of androgen receptor mutation is essential, as majority of clinically suspected PAIS lack AR gene mutations (AIS type II) 12

Monitoring Parameters

Unlike standard testosterone replacement monitoring 5, 6, PAIS patients require:

• Baseline and periodic testosterone, LH, FSH, estradiol levels (expect elevated testosterone/LH)
• Semen analysis if fertility desired
• Psychological assessment for gender dysphoria
• Breast examination for gynecomastia progression
• Testicular examination if testes retained

The management paradigm for PAIS is fundamentally different from classical hypogonadism—focus on surgical correction, selective use of topical DHT in youth, gonadotropins for fertility, and comprehensive psychological support rather than systemic testosterone replacement.